NCT01324440View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions
Staphylococcal Infections
Interventions
BIOLOGICAL

V710 (30 µg) with MAA

Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly

BIOLOGICAL

V710 (30 µg) without MAA

Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01324440 - Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002) | Biotech Hunter | Biotech Hunter